Procedure Code,Description,O.R.,Lists
0J9J3ZZ,"Drainage of Right Hand Subcutaneous Tissue and Fascia, Percutaneous Approach",Y,D477
0J9K3ZZ,"Drainage of Left Hand Subcutaneous Tissue and Fascia, Percutaneous Approach",Y,D477
0UBMXZZ,"Excision of Vulva, External Approach",Y,U468
3E0P76Z,"Introduction of Nutritional Substance into Female Reproductive, Via Natural or Artificial Opening",,NONOR
3E0P77Z,"Introduction of Electrolytic and Water Balance Substance into Female Reproductive, Via Natural or Artificial Opening",,NONOR
3E0P7GC,"Introduction of Other Therapeutic Substance into Female Reproductive, Via Natural or Artificial Opening",,NONOR
3E0P7SF,"Introduction of Other Gas into Female Reproductive, Via Natural or Artificial Opening",,NONOR
3E0P83Z,"Introduction of Anti-inflammatory into Female Reproductive, Via Natural or Artificial Opening Endoscopic",,NONOR
3E0P86Z,"Introduction of Nutritional Substance into Female Reproductive, Via Natural or Artificial Opening Endoscopic",,NONOR
3E0P87Z,"Introduction of Electrolytic and Water Balance Substance into Female Reproductive, Via Natural or Artificial Opening Endoscopic",,NONOR
3E0P8GC,"Introduction of Other Therapeutic Substance into Female Reproductive, Via Natural or Artificial Opening Endoscopic",,NONOR
3E0P8SF,"Introduction of Other Gas into Female Reproductive, Via Natural or Artificial Opening Endoscopic",,NONOR
XR2G021,"Monitoring of Right Knee Joint using Intraoperative Knee Replacement Sensor, Open Approach, New Technology Group 1",,Y,D477
XR2H021,"Monitoring of Left Knee Joint using Intraoperative Knee Replacement Sensor, Open Approach, New Technology Group 1",Y,,D477
XW03321,"Introduction of Ceftazidime-Avibactam Anti-infective into Peripheral Vein, Percutaneous Approach, New Technology Group 1",,NONOR
XW03331,"Introduction of Idarucizumab, Dabigatran Reversal Agent into Peripheral Vein, Percutaneous Approach, New Technology Group 1",,NONOR
XW03341,"Introduction of Isavuconazole Anti-infective into Peripheral Vein, Percutaneous Approach, New Technology Group 1",,NONOR
XW03351,"Introduction of Blinatumomab Antineoplastic Immunotherapy into Peripheral Vein, Percutaneous Approach, New Technology Group 1",,NONOR
XW04321,"Introduction of Ceftazidime-Avibactam Anti-infective into Central Vein, Percutaneous Approach, New Technology Group 1",,NONOR
XW04331,"Introduction of Idarucizumab, Dabigatran Reversal Agent into Central Vein, Percutaneous Approach, New Technology Group 1",,NONOR
XW04341,"Introduction of Isavuconazole Anti-infective into Central Vein, Percutaneous Approach, New Technology Group 1",,NONOR
XW04351,"Introduction of Blinatumomab Antineoplastic Immunotherapy into Central Vein, Percutaneous Approach, New Technology Group 1",,NONOR
